Use of the cathelicidin LL-37 and derivatives therof for wound healing
AssigneeLipopeptide AB
InventorsMona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
Life of this patent
Estimating the term…
Abstract
Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.
Claims1
A method of stimulating proliferation of keratinocytes for cell transplantation of ulcers and burns in a patient;
- which comprises;
- obtaining autologous human keratinocytes from a healthy skin piece excised from the patient;
- transfecting the keratinocytes with a full-length hCAP18 cDNA construct;
- and
- transplanting the transfected keratinocytes back into the patient.
Dependencies are inferred from the claim text.